Resource Alert! - Caring for Trafficked Persons: Guidance for Health Providers Facilitator’s Guide
July 19, 2015
Unmasking Cancer as a Consequence of Human Trafficking: A Multidisciplinary Challenge
July 14, 2015
Sexual Abuse, The Prison Pipeline, and the Young Girls of Color
July 19, 2015
Cancer Drugs’ Effectiveness Do Not Match Their Cost
November 14, 2015
By Luis Gay
In the past, whenever a cancer drug was created and released, people became excited. However, no one blinks an eye anymore because new treatments cost hundreds of thousands of dollars, far out of reach for many cancer patients. Along with costs, many new treatments are therapies/drugs that target cancers with specific mutations. As a result, only few people benefit. Pharmaceutical companies are given some slack when pricing these types of drugs as limited amount of people makes it difficult to recoup investments. Because of precision targeting, people are hopeful that new treatments will be more effective against cancer and makes up for how expensive they are, but this is not the case.
Shop Women's Outerwear at Timberland and Get Free Shipping Over $100.
Use the Coupon Code: ship100
In a study conducted by David H. Howard entitled Pricing in the Market for Anticancer Drugs, Howard and his colleagues explained that new cancer treatments (on average) are less cost-effective than older ones. In other words, the price of cancer drugs is escalating faster than their effectiveness. This is determined by the ratio of how much a drug raises healthcare cost and how much it improves someone’s overall health. This is particularly important for treatments in advanced cancers. For instance, let us say that a $200,000 treatment increases life expectancy by an average of a year. This ratio is on the border of what health policy experts believe is worth spending for a year of life. If the quality of life deviated any lower, the treatment would be less cost-effective.
In the study, Howard and colleagues plotted cost-effectiveness over time. They discovered that the price of an extra year of life has increased even after adjusting for inflation. In the mid-nineties, an extra year cost below $100,000. In comparison, newer treatments cost as much as $20,000 or higher.
The trend of declining cost-effectiveness is a very disturbing phenomenon. Outliers on the graph are even more disturbing. One treatment goes as far as providing a year of life for $800,000. This is highly unacceptable. High prices need to reflect significant benefits. There is no value in a drug if people cannot afford to use them.
Free Shipping on orders over $59
Luis Gay is a sophomore attending the University of San Francisco, pursuing a Biology degree and Biochemistry Minor. He is a Social Media Assistant at Cancer InCytes Magazine.
Ubel, Peter. 30Sept2015. “Cancer Drugs Aren't As Cost-Effective As They Used To Be”. Forbes. [Accessed 9 Oct 2015]
This photo can be found at the University of Mississippi Medical Center’s Website.